Is the Vagina the New Face?

Where the Phrase Comes From

The expression "the vagina is the new face" emerged from aesthetic medicine marketing around 2016 and 2017, when device manufacturers began repositioning fractional CO2 lasers and radiofrequency platforms for vulvovaginal use. The logic was straightforward: if controlled thermal injury can stimulate collagen remodeling in facial skin, the same principle might restore elasticity and hydration to vaginal mucosa.

A Marketing Phrase With Clinical Roots

The comparison is not entirely superficial. Vaginal epithelium and facial skin share certain structural features, including estrogen receptors that regulate collagen density, glycogen content, and mucosal thickness. Estrogen withdrawal after menopause thins both tissues. A 2019 review in Menopause noted that vaginal epithelium loses approximately 50% of its collagen content within 3 years of final menstrual period [1]. That parallel gave device companies a persuasive pitch.

The Market Explosion

The American Society of Plastic Surgeons (ASPS) reported that cosmetic vaginal procedures increased 30% between 2018 and 2022 [2]. Labiaplasty alone rose 36% over a similar window. Google Trends data shows search volume for "vaginal rejuvenation" tripled between 2015 and 2023. The market now includes fractional CO2 lasers, erbium:YAG lasers, monopolar and bipolar radiofrequency devices, platelet-rich plasma injections, hyaluronic acid fillers, and an expanding shelf of vulvar-specific skincare products.

But popularity is not proof. The question is which of these interventions have evidence, which address real pathology, and which are solutions looking for a problem.

Genitourinary Syndrome of Menopause: The Actual Medical Problem

GSM replaced the older term "vulvovaginal atrophy" in 2014 when the International Society for the Study of Women's Sexual Health (ISSWSH) and NAMS jointly adopted the new terminology [3]. The name change was not cosmetic. GSM captures a broader symptom cluster: vaginal dryness, burning, irritation, dyspareunia (painful intercourse), urinary urgency, recurrent UTIs, and post-coital bleeding.

How Common Is GSM?

Prevalence estimates range from 50% to 84% of postmenopausal women depending on the screening method [4]. A 2021 cross-sectional study published in Maturitas (N=2,160) found that 67% of women between ages 55 and 75 reported at least one moderate-to-severe GSM symptom, yet only 7% had received any treatment [5]. The treatment gap is enormous.

Why GSM Is Undertreated

Three factors drive under-treatment. Patients feel embarrassed to raise the topic. Clinicians often skip the question during routine visits. And persistent confusion about hormone therapy safety (rooted in misinterpretation of the 2002 Women's Health Initiative findings) makes both patients and providers hesitant about vaginal estrogen, even though local formulations carry minimal systemic absorption [6].

This treatment gap created the opening for device-based and non-hormonal alternatives marketed directly to consumers.

Vaginal Estrogen: What the Evidence Actually Supports

Low-dose vaginal estrogen is the gold-standard treatment for GSM. The 2022 NAMS position statement reaffirmed this, concluding that vaginal estrogen is effective, safe, and appropriate even for most women with a history of hormone-sensitive breast cancer when used at the lowest effective dose [7].

Formulations and Dosing

Available formulations include vaginal estradiol tablets (10 mcg, brand name Vagifem/Yuvafem), estradiol cream (Estrace), conjugated estrogen cream (Premarin), and the estradiol ring (Estring, delivering 7.5 mcg/day over 90 days). A 2016 pharmacokinetic study in Menopause showed that the 10 mcg estradiol tablet maintained serum estradiol levels below 5 pg/mL after 12 weeks, within the normal postmenopausal range [8].

Efficacy Data

The Cochrane Review on local estrogen for vaginal atrophy (2006, updated 2016) pooled 30 RCTs and found that all low-dose vaginal estrogen formulations significantly improved vaginal maturation index, pH, and symptom scores compared to placebo, with no significant differences between formulations [9]. Response rates exceed 80% in most trials.

The Breast Cancer Question

The 2024 ASCO/ISSWSH joint guideline stated that vaginal estrogen at approved low doses "does not appear to increase recurrence risk in women on aromatase inhibitors," though it recommended shared decision-making and monitoring for patients on active endocrine therapy [10]. Serum levels remain within the postmenopausal range with all low-dose formulations.

Energy-Based Devices: Lasers and Radiofrequency

Fractional CO2 lasers (MonaLisa Touch, FemTouch) and erbium:YAG lasers (Juliet, IntimaLase) create controlled micro-injuries in vaginal epithelium. Radiofrequency devices (ThermiVa, Viveve, votiva) deliver thermal energy to stimulate collagen remodeling. The proposed mechanism mirrors facial resurfacing: controlled damage triggers a wound-healing cascade that increases collagen, elastin, and vascularity.

What the Trials Show

The VELAS trial (2021, N=85), a double-blind sham-controlled RCT published in JAMA, compared fractional CO2 laser to sham treatment for GSM. At 6 months, both groups improved. The laser group showed no statistically significant benefit over sham for the primary endpoint of most bothersome symptom severity (mean difference 0.24, 95% CI: -0.26 to 0.73) [11]. This was the first rigorous sham-controlled trial, and it challenged years of positive results from unblinded, manufacturer-funded studies.

The FDA Warning

In July 2018, the FDA issued safety communications to seven device manufacturers, warning against unapproved marketing of energy-based devices for "vaginal rejuvenation" or treatment of sexual dysfunction, urinary incontinence, or GSM symptoms [12]. The FDA stated it had received reports of burns, scarring, dyspareunia, and chronic pain following these procedures. No fractional CO2 or RF device currently holds FDA clearance specifically for GSM treatment.

Where Energy Devices May Still Have a Role

The LADYBIRD trial (2023, N=152), an Australian RCT comparing CO2 laser, topical estrogen, and sham, found the laser group had modest improvements in dyspareunia scores at 12 months, though vaginal estrogen performed similarly [13]. Some gynecologists still offer laser as a second-line option for women who cannot or will not use vaginal estrogen, but this remains an off-label, out-of-pocket treatment without guideline endorsement.

A typical three-session course of vaginal laser costs between $1,500 and $4,500 in the United States, with no insurance coverage.

PRP and the "O-Shot": What's Missing

Platelet-rich plasma (PRP) injection into the anterior vaginal wall and clitoris (branded as the "O-Shot") has been marketed for sexual arousal disorder, stress urinary incontinence, and vaginal dryness. The treatment concentrates autologous growth factors and injects them into target tissue.

The Evidence Gap

As of May 2026, no phase III RCT has evaluated PRP for any vulvovaginal indication. A 2022 systematic review in The Journal of Sexual Medicine identified 11 studies (total N=379), all observational or pilot-sized, with high risk of bias across every domain [14]. Several showed subjective improvement in Female Sexual Function Index (FSFI) scores, but without sham controls, placebo effects cannot be excluded.

The procedure costs $1,200 to $2,000 per session. It is not FDA-approved for vulvovaginal use.

Hyaluronic Acid: Topical and Injectable

Hyaluronic acid (HA) is used two ways in vaginal health: as a non-hormonal topical moisturizer and as an injectable filler for the labia majora and G-spot area.

Topical HA for GSM

A 2021 multicenter RCT published in Obstetrics & Gynecology (N=195) compared vaginal HA gel to vaginal estrogen cream for GSM over 12 weeks. Both groups showed significant improvement in vaginal dryness and dyspareunia scores from baseline, with no statistically significant difference between groups for the primary outcome [15]. Topical HA represents a genuine non-hormonal option with reasonable evidence, though long-term data beyond 12 weeks is limited.

Injectable HA

Injectable HA for labial or vaginal augmentation is performed off-label. No RCT has evaluated safety or efficacy for these indications. Reported complications include vascular occlusion, granuloma formation, and asymmetry. The procedure is purely cosmetic.

Vulvar Skincare: The Consumer Product Boom

A parallel market has emerged in vulvar-specific skincare: moisturizers, serums, pH-balanced washes, and "intimate masks" positioned alongside facial skincare routines. The global feminine hygiene market reached $40.2 billion in 2023, per Grand View Research.

What Gynecologists Recommend

The American College of Obstetricians and Gynecologists (ACOG) advises against douching and recommends only warm water or mild, unscented soap for external vulvar cleansing [16]. The vaginal microbiome is self-regulating. Products that alter vaginal pH or introduce fragrances increase risk of bacterial vaginosis and contact dermatitis.

Where External Products Help

Vulvar barrier creams containing petrolatum or dimethicone may protect irritated vulvar skin. Water-based or silicone-based lubricants reduce friction-related dyspareunia. These are inexpensive, evidence-supported interventions. The branded "vulvar serums" priced at $60 to $120 per ounce typically contain the same active ingredients as standard moisturizers at a significant markup.

Labiaplasty: Surgical Aesthetics

Labiaplasty (surgical reduction of the labia minora) is the fastest-growing cosmetic gynecologic procedure. ASPS recorded 13,840 labiaplasties in the United States in 2022, up from 10,133 in 2017 [2].

Medical vs. Cosmetic Indications

Labial hypertrophy can cause functional symptoms: chafing during exercise, discomfort in fitted clothing, pain during intercourse, and difficulty with hygiene. When these functional complaints are documented, labiaplasty has a clear medical indication.

The concern centers on cosmetic-only procedures driven by distorted body-image norms. A 2020 survey in Aesthetic Surgery Journal (N=482) found that 56% of women seeking labiaplasty cited appearance as their primary motivation, with 31% referencing comparisons to images seen in media or pornography [17].

ACOG's Position

ACOG's 2020 Committee Opinion stated that patients requesting cosmetic vaginal procedures should receive counseling that "normal genital appearance varies widely" and that data on long-term safety and sexual satisfaction outcomes remain limited [18]. The committee recommended against labiaplasty in adolescents except for documented functional impairment.

Who Actually Benefits and Who Gets Oversold

The "vagina is the new face" framing conflates two distinct populations. The first group is postmenopausal women with symptomatic GSM who need and deserve treatment, primarily vaginal estrogen or non-hormonal alternatives like ospemifene (Osphena, an oral SERM) or topical HA. The second group is premenopausal women with normal anatomy being marketed cosmetic procedures that lack evidence.

A Decision Framework

For GSM symptoms (dryness, dyspareunia, recurrent UTI): start with low-dose vaginal estrogen or topical HA gel. These are the only interventions with consistent RCT support.

For stress urinary incontinence: pelvic floor physical therapy remains first-line per the 2023 AUA/SUFU guideline [19]. Energy-based devices are not recommended.

For cosmetic concerns without functional symptoms: understand that no device or injectable has proven long-term aesthetic outcomes in vulvovaginal tissue. The risk-benefit calculus is different from facial aesthetics, where decades of outcome data exist.

For labial discomfort causing functional limitations: labiaplasty with a board-certified surgeon (ABOG or ABPS) after conservative measures fail is a reasonable option.

What the Trend Gets Right and Wrong

The positive dimension of this trend is visibility. Women's sexual health has been under-discussed, under-researched, and under-funded for decades. The NIH allocated only 4.8% of its sexual medicine research budget to female-specific conditions in 2022 [20]. If consumer demand drives more clinical trials and FDA-cleared devices, that benefits patients.

The Risk of Premature Commercialization

The negative dimension is that commercial interest has outpaced evidence. Procedures with no sham-controlled RCT support are being offered at premium prices. The 2018 FDA safety communications remain in effect, yet marketing for vaginal laser and RF treatments continues on social media platforms with limited regulatory oversight.

"Board-certified in obstetrics and gynecology" is a necessary credential for any provider offering these treatments. "Board-certified in aesthetic medicine" or "certified laser technician" without OB-GYN or urogynecology training is a red flag, not a reassurance.

Women experiencing vaginal dryness, pain during sex, or urinary symptoms after menopause should ask their clinician about vaginal estradiol 10 mcg tablets or the 90-day estradiol ring as first-line treatment, both of which maintain serum estradiol below the postmenopausal threshold of 20 pg/mL [8].